🔬 The Cell and Gene Therapy Catapult is developing systems for high cell density transfection.
⚙️ Their goal is to improve productivity during production and reduce costs for therapies.
🧪 By adapting methods from monoclonal antibody production and addressing technical obstacles, they aim to streamline AAV manufacturing.
Introduction:
The article discusses the advancements made by the Cell and Gene Therapy Catapult, a UK organization, in addressing the challenges associated with continuous manufacturing of Adeno-Associated Viruses (AAV). This innovation is crucial for enhancing the efficiency and cost-effectiveness of gene therapy production as the demand for systemic therapies increases.
- The Cell and Gene Therapy Catapult is working on continuous upstream processing for AAV production, integrating high cell density transfection and continuous perfusion systems.
- A platform for high density continuous harvest has been developed, demonstrating proof-of-concept data.
- Continuous processing is established in monoclonal antibody production but is gaining traction for AAV as manufacturers focus on therapies for systemic diseases.
- Technical challenges such as high-density cell transfection and product loss during perfusion pose barriers to the adoption of continuous processing.
- The team at CGT Catapult developed solutions using Design of Experiment (DOE) methodologies and alternative filtration methods to improve transfection efficiency and continuous harvest effectiveness.
Conclusion:
The Cell and Gene Therapy Catapult’s work on continuous manufacturing for AAV illustrates the potential to optimize production and reduce costs in gene therapies. The ongoing integration of transfection and continuous harvest processes signifies a step toward overcoming current technical obstacles, ultimately enhancing the accessibility and efficiency of crucial therapeutic products.
